Purchase Order 36C24526P0413
Award Date 5/19/26
Potential Completion Date 5/20/26
Potential Value $38K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Brooks, KY 40109, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, Veterans Integrated Service Network 2 (VISN 2) awarded a firm fixed-price purchase order to Theracom, L.L.C. for TAKHZYRO 150MG/ML injection in 2ML syringe formulation on February 24, 2026. The contract has a ceiling value of $38,875.02 with an ultimate completion date of March 24, 2026. The award was made without a set-aside designation, reflecting full and open competition. Theracom, a Kentucky-based pharmaceutical specialty distributor headquartered in...
- Theracom, L.L.C., a child entity, has been awarded a firm fixed price purchase order by the Veterans Integrated Service Network 2 (VISN 2), a civilian component of the Department of Veterans Affairs, for the supply of TAKHZYRO 150MG. The contract, issued on December 1, 2025, carries a ceiling value of $75,478.12 and is scheduled for ultimate completion by December 30, 2025. The contract was awarded without a set-aside designation and will be performed in Brooks, Kentucky. TAKHZYRO...
- The Department of Veterans Affairs, Veterans Integrated Service Network 2 (VISN 2) awarded a $38,875.02 firm fixed-price purchase order to Theracom, L.L.C. on March 18, 2026 for the supply of TAKHZYRO 150MG/ML injection in 2ML syringe formulation. The contract, which will be completed by March 25, 2026, was awarded without a set-aside designation and will be performed at Theracom's location in Brooks, Kentucky. Theracom is a specialty pharmaceutical distributor headquartered in Shepherdsville,...
- Theracom, L.L.C., a child entity, was awarded a firm fixed-price purchase order by Veterans Integrated Service Network 2 on October 20, 2025, for the supply of TAKHZYRO (pegtanercept) 150MG/ML injection in a 2ML syringe formulation. This is a pharmaceutical supply contract with a ceiling value of approximately $37.7K, with an ultimate completion date of November 20, 2025. The contract was awarded without a set-aside designation, and the place of performance is listed as Brooks, Kentucky. This...
- On February 5, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 MG, a specialized pharmaceutical treatment for rare genetic disorders. This firm fixed-price delivery order is issued under a parent Blanket Purchase Agreement established on the General Services Administration Pharmaceuticals and Drugs Schedule (FSS-61-IB), which provides streamlined...
- On November 7, 2025, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a firm fixed-price delivery order valued at $36,984.28 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. This delivery order represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries an ultimate completion date of November 13, 2025. The award was made without a...
- On January 15, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for TAKHZYRO 150 MG, a specialized pharmaceutical product used to treat rare genetic disorders. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not utilize a set-aside...
- On December 16, 2025, the Department of Veterans Affairs Veterans Integrated Service Network 5 awarded a firm fixed-price delivery order valued at $36,984.28 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 mg, a specialized pharmaceutical treatment for hereditary angioedema. This delivery order represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries an ultimate completion date of December 18, 2025. The contract was awarded...
- Takeda Pharmaceuticals America Inc. was awarded a $36,984.28 firm fixed-price delivery order for TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. The contract, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, is a child order under Takeda's broader Blanket Purchase Agreement with the VA National Acquisition Center valued at $131.04 million. The award was issued without a set-aside designation, reflecting the specialized and...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded Takeda Pharmaceuticals America Inc. a $36,890.40 firm fixed price delivery order for TAKHZYRO under the company's Pharmaceuticals and Drugs General Services Administration schedule contract. TAKHZYRO will be delivered to facilities in Lexington, Massachusetts by June 7, 2024 to support treatment of hereditary angioedema. No set-aside was applied given the specialized nature of the...